Mizuho Securities Reaffirms Their Buy Rating on Assembly Biosciences (ASMB)

Tip Ranks
2025.11.19 21:35
portai
I'm PortAI, I can summarize articles.

Mizuho Securities analyst Salim Syed reaffirmed a Buy rating on Assembly Biosciences (ASMB) with a price target of $40. H.C. Wainwright also issued a Buy rating, while another firm reiterated a Hold rating. Syed, who covers the Healthcare sector, has an average return of -4.1% and a 41.09% success rate on stock recommendations.

Mizuho Securities analyst Salim Syed maintained a Buy rating on Assembly Biosciences today and set a price target of $40.00.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

Syed covers the Healthcare sector, focusing on stocks such as BridgeBio Pharma, Biogen, and Incyte. According to TipRanks, Syed has an average return of -4.1% and a 41.09% success rate on recommended stocks.

In addition to Mizuho Securities, Assembly Biosciences also received a Buy from H.C. Wainwright’s Patrick Trucchio in a report issued on November 14. However, on November 13, TR | OpenAI – 4o reiterated a Hold rating on Assembly Biosciences (NASDAQ: ASMB).

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer